What is claimed is:

## 1. A compound of Formula I

wherein

5

10

15

20

25

R<sup>1</sup> is selected from H, F, and Cl;

R<sup>2</sup> is selected from H, OH, CN, halo, C(O)R<sup>5</sup>, thienyl, pyrimidinyl, oxazolyl, furanyl,

 $(C_1-C_3)$ alkyl,  $(C_2-C_6)$ alkenyl and  $(C_2-C_6)$ alkynyl, each optionally substituted with up to two substituents selected from OH, halo, and  $(C_1-C_3)$ alkoxy optionally substituted with  $(C_1-C_3)$ alkoxy,

 $(C_1-C_6)$ alkoxy optionally substituted with  $(C_1-C_3)$ alkyl,  $(C_1-C_3)$ alkoxy,

pyrrolidinyl, 
$$+$$
N $\times$ 

and  $N[(C_1-C_3)alkyl]_2$  where each alkyl group is independently optionally substituted with a substituent selected from  $(C_1-C_3)alkyl$ ,

$$(C_1-C_3)$$
alkoxy OH, halo,  $\stackrel{+}{\longrightarrow}$ , and phenyl,

N[(C<sub>1</sub>-C<sub>4</sub>)alkyl]<sub>2</sub> where each alkyl group is independently optionally substituted with up to two substituents independently selected from OH, (C<sub>1</sub>-C<sub>3</sub>)alkyl, halo, (C<sub>1</sub>-C<sub>3</sub>)alkoxy, and phenyl,

pyridyl optionally substituted with up to two substituents independently selected from (C<sub>1</sub>-C<sub>3</sub>)alkyl, (C<sub>1</sub>-C<sub>3</sub>)alkoxy, and halo,

phenyl optionally substituted with up to two substituents independently selected

from 
$$(C_1-C_3)$$
alkoxy, CN, halo,  $+N$  ,  $C(O)-N$   $X$ 

 $C(O)N[(C_1-C_3)alkyl]_2$  where each alkyl is optionally substituted with

(C₁-C₃)alkoxy, and

pyrrolidinyl optionally substituted with  $N[(C_1-C_3)alkyl]_2$ ;

 $R^3$  is selected from H, halo, (C<sub>1</sub>-C<sub>3</sub>)alkyl, and (C<sub>1</sub>-C<sub>3</sub>)alkoxy;

R<sup>4</sup> is selected from H, F, and Cl;

R<sup>5</sup> is selected from OH, NHR<sup>6</sup>,

10

15

20

25

30

$N[(C_1-C_3)alkyl]R^7$ where said alkyl is optionally substituted with up to	one
substituent selected from $(C_1-C_3)$ alkyl and $(C_1-C_3)$ alkoxy,	

 $N[(C_1-C_3)alkyl]_2 \ where each alkyl is optionally substituted with up to two substituents independently selected from CN, OH, (C_1-C_3)alkoxy, <math display="block">N[(C_1-C_3)alkyl]_2, \ pyridyl, \ phenyl, \ S(O)_2(C_1-C_3)alkyl, \ tetrahydrofuryl, \\ S(O)_2-phenyl, \ (C_3-C_6)cycloalkyl, \ and \\ furyl \ optionally \ substituted \ with \ (C_1-C_3)alkyl, \\$ 

 $\label{eq:Newtonical} N[(C_3-C_6) \text{cycloalkyl}](C_1-C_3) \text{alkyl} \text{ where said alkyl is substituted with up to two substituents independently selected from } (C_1-C_3) \text{alkoxy, OH, CN, } \\ N[(C_1-C_4) \text{alkyl}]_2, \ S(O)_2-\text{phenyl, } S(O)_2(C_1-C_3) \text{alkyl, phenyl, furyl, } \\ \text{tetrahydrofuryl, } (C_5-C_6) \text{cycloalkyl, and pyridyl, } \\$ 

optionally substituted with up to two substituents independently selected from N[(C<sub>1</sub>-C<sub>3</sub>)alkyl]<sub>2</sub>, C(O)(C<sub>1</sub>-C<sub>3</sub>)alkyl, pyrrolidinyl,

 $S(O)_2(C_1-C_3)$ alkyl,  $S(O)_2$ -phenyl, , oxo-dihydrobenzimidazolyl, pyrazinyl,  $C(O)NH_2$ , C(O)NH-phenyl, C(O)-furanyl,  $C(O)NH(C_1-C_3)$ alkyl,  $(C_1-C_3)$ alkyl optionally substituted with up to two substituents

independently selected from OH, halo, (C<sub>1</sub>-C<sub>3</sub>)alkoxy,

pyrrolidinyl, C(O)-pyrrolidinyl, C(O)-N , and N[(C<sub>1</sub>-C<sub>3</sub>)alkyl]<sub>2</sub>, phenyl optionally substituted with up to two substituents independently selected from (C<sub>1</sub>-C<sub>3</sub>)alkyl, (C<sub>1</sub>-C<sub>3</sub>)alkoxy, halo, CF<sub>3</sub>, and CN, and pyridyl optionally substituted with (C<sub>1</sub>-C<sub>3</sub>)alkyl, CF<sub>3</sub>, and CN, and pyrrolidinyl optionally substituted with up to two substituents independently selected from N[(C<sub>1</sub>-C<sub>4</sub>)alkyl]<sub>2</sub>, C(O)NH<sub>2</sub>, pyridyl, and (C<sub>1</sub>-C<sub>3</sub>)alkyl optionally substituted with up to two substituents independently selected from (C<sub>1</sub>-C<sub>3</sub>)alkoxy, and pyrrolidinyl;

R<sup>6</sup> is selected from H,

 $(C_1-C_4)$ alkyl optionally substituted with up to two substituents independently selected from OH, halo,  $(C_1-C_4)$ alkoxy, NHC(O) $(C_1-C_3)$ alkyl,

S-(C<sub>1</sub>-C<sub>3</sub>)alkyl, benzimidazolyl, thienyl, ..., N[(C<sub>1</sub>-C<sub>4</sub>)alkyl]<sub>2</sub> where each alkyl is independently optionally substituted with up to two substituents independently selected from OH, (C<sub>1</sub>-C<sub>3</sub>)alkoxy, halo, and phenyl,

10

15

20

25

phenyl optionally substituted with up to two substituents independently selected from  $(C_1-C_3)$ alkyl,  $(C_1-C_3)$ alkoxy, CN, halo,  $CF_3$ ,  $S(O)_2(C_1-C_3)$ alkyl,  $S(O)_2$ phenyl, and  $S(O)_2NH_2$ , pyridyl optionally substituted up to two times with CF<sub>3</sub>, indolyl optionally substituted up to two times with (C<sub>1</sub>-C<sub>3</sub>)alkyl, imidazolyl optionally substituted up to two times with (C<sub>1</sub>-C<sub>3</sub>)alkyl, furyl optionally substituted up to two times with (C<sub>1</sub>-C<sub>4</sub>)alkyl, and pyrrolidinyl optionally substituted with up to two substituents independently selected from (C<sub>1</sub>-C<sub>4</sub>)alkoxy, (O), and (C<sub>1</sub>-C<sub>4</sub>)alkyl optionally substituted with up to two substituents independently selected from OH, (C<sub>1</sub>-C<sub>3</sub>)alkoxy, and halo, indolyl optionally substituted up to two times with (C1-C3)alkyl, pyrazolyl optionally substituted with up to two substituents independently selected from (C<sub>1</sub>-C<sub>4</sub>)alkyl, (C<sub>3</sub>-C<sub>6</sub>)cycloalkyl, and phenyl optionally substituted with up to two substituents independently selected from (C<sub>1</sub>-C<sub>4</sub>)alkoxy, (C<sub>1</sub>-C<sub>4</sub>)alkyl, halo, CF<sub>3</sub>, and CN, benzothiazolyl optionally substituted up to two times with (C1-C4)alkyl, thiazolyl optionally substituted up to two times with (C<sub>1</sub>-C<sub>4</sub>)alkyl, thiadiazolyl optionally substituted with up to two substituents independently selected from CF<sub>3</sub>, (C<sub>3</sub>-C<sub>6</sub>)cycloalkyl, and (C<sub>1</sub>-C<sub>6</sub>)alkyl, phenyl optionally substituted with up to two substituents independently selected from CN, halo,  $CF_3$ ,  $N[(C_1-C_4)alkyl]_2$ , indolyl,  $\stackrel{+}{\longrightarrow}$ ,  $(C_1-C_4)alkoxy$ , O-pyridyl optionally substituted with C(O)NH(C<sub>1</sub>-C<sub>4</sub>)alkyl, (C₁-C₄)alkyl optionally substituted with up to two substituents independently selected from pyridyl, OH, halo, and phenyl, and optionally substituted with up to two substituents independently selected from (C<sub>1</sub>-C<sub>3</sub>)alkyl, and(C<sub>1</sub>-C<sub>4</sub>)alkoxy, pyridyl optionally substituted with phenoxy where said phenoxy is optionally substituted with up to two substituents independently selected from (C<sub>1</sub>-C<sub>4</sub>)alkyl and (C<sub>1</sub>-C<sub>4</sub>)alkoxy, and

30

indazolyl optionally substituted up to two times with  $(C_1-C_4)$ alkyl;  $R^7$  is selected from  $(C_1-C_3)$ alkoxy, pyrrolidinyl, tetrahydropyranyl, pyridyl optionally substituted with up to two substituents independently selected from  $(C_1-C_4)$ alkyl and  $(C_1-C_3)$ alkoxy,

pyranyl optionally substituted with up to two substituents independently selected from  $(C_1-C_4)$ alkyl and  $(C_1-C_3)$ alkoxy,

piperidinyl optionally substituted with up to two substituents independently selected from  $(C_1-C_3)$ alkyl, and  $(C_1-C_3)$ alkoxy, and

phenyl optionally substituted with up to two substituents independently selected from  $(C_1-C_3)$ alkoxy, and  $(C_1-C_3)$ alkyl; and

X is selected from O, S, CH<sub>2</sub> and NH;

with the proviso that when R<sup>1</sup> is F or Cl, then R<sup>4</sup> must be H, and when R<sup>4</sup> is F or Cl, then R<sup>1</sup> must be H;

or a pharmaceutically acceptable salt thereof.

 A method of treating a disorder selected from a hyper-proliferative disorder and a disorder associated with angiogenesis, in a mammal in need thereof, comprising administering to said mammal an effective amount of a compound of Formula I

$$\begin{array}{c|c}
R^1 & R^2 \\
R^2 & R^3 \\
R^4 & R^4
\end{array}$$
(I)

15

20

5

10

wherein

R<sup>1</sup> is selected from H, F, and Cl;

R<sup>2</sup> is selected from H, OH, CN, halo, C(O)R<sup>5</sup>, thienyl, pyrimidinyl, oxazolyl, furanyl,

(C<sub>1</sub>-C<sub>3</sub>)alkyl, (C<sub>2</sub>-C<sub>6</sub>)alkenyl and (C<sub>2</sub>-C<sub>6</sub>)alkynyl, each optionally substituted with up to two substituents selected from OH, halo, and (C<sub>1</sub>-C<sub>3</sub>)alkoxy optionally substituted with (C<sub>1</sub>-C<sub>3</sub>)alkoxy,

 $(C_1-\dot{C}_6)$ alkoxy optionally substituted with  $(C_1-C_3)$ alkyl,  $(C_1-C_3)$ alkoxy,

pyrrolidinyl, 
$$+$$
N $\longrightarrow$ 

pyrrolidin 25 and N[(C

and  $N[(C_1-C_3)alkyl]_2$  where each alkyl group is independently optionally substituted with a substituent selected from  $(C_1-C_3)alkyl$ ,

$$(C_1-C_3)$$
alkoxy OH, halo,  $+N$ , and phenyl

N[(C<sub>1</sub>-C<sub>4</sub>)alkyl]<sub>2</sub> where each alkyl group is independently optionally substituted with up to two substituents independently selected from OH, (C<sub>1</sub>-C<sub>3</sub>)alkyl, halo, (C<sub>1</sub>-C<sub>3</sub>)alkoxy, and phenyl,

pyridyl optionally substituted with up to two substituents independently selected from  $(C_1-C_3)$ alkyl,  $(C_1-C_3)$ alkoxy, and halo,

phenyl optionally substituted with up to two substituents independently selected

 $C(O)N[(C_1-C_3)alkyl]_2$  where each alkyl is optionally substituted with  $(C_1-C_3)alkoxy$ , and

pyrrolidinyl optionally substituted with N[(C<sub>1</sub>-C<sub>3</sub>)alkyl]<sub>2</sub>;

 $R^3$  is selected from H, halo,  $(C_1-C_3)$ alkyl, and  $(C_1-C_3)$ alkoxy;

R<sup>4</sup> is selected from H, F, and Cl;

R<sup>5</sup> is selected from OH, NHR<sup>6</sup>,

 $N[(C_1-C_3)alkyl]R^7$  where said alkyl is optionally substituted with up to one substituent selected from  $(C_1-C_3)alkyl$  and  $(C_1-C_3)alkoxy$ ,

$$\label{eq:Newtonian} \begin{split} &N[(C_1-C_3)alkyl]_2 \text{ where each alkyl is optionally substituted with up to two} \\ &\text{substituents independently selected from CN, OH, } (C_1-C_3)alkoxy, \\ &N[(C_1-C_3)alkyl]_2, \text{ pyridyl, phenyl, } S(O)_2(C_1-C_3)alkyl, \text{ tetrahydrofuryl, } \\ &S(O)_2\text{-phenyl, } (C_3-C_6)\text{cycloalkyl, and} \\ &\text{furyl optionally substituted with } (C_1-C_3)alkyl, \end{split}$$

N[(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl](C<sub>1</sub>-C<sub>3</sub>)alkyl where said alkyl is substituted with up to two substituents independently selected from (C<sub>1</sub>-C<sub>3</sub>)alkoxy, OH, CN, N[(C<sub>1</sub>-C<sub>4</sub>)alkyl]<sub>2</sub>, S(O)<sub>2</sub>-phenyl, S(O)<sub>2</sub>(C<sub>1</sub>-C<sub>3</sub>)alkyl, phenyl, furyl, tetrahydrofuryl, (C<sub>5</sub>-C<sub>6</sub>)cycloalkyl, and pyridyl,

optionally substituted with up to two substituents independently selected from N[(C<sub>1</sub>-C<sub>3</sub>)alkyl]<sub>2</sub>, C(O)(C<sub>1</sub>-C<sub>3</sub>)alkyl, pyrrolidinyl,

 $S(O)_2(C_1-C_3)$ alkyl,  $S(O)_2$ -phenyl,  $\overset{\cdot}{\longrightarrow}\overset{\cdot}{\searrow}$ , oxo-dihydrobenzimidazolyl, pyrazinyl,  $C(O)NH_2$ , C(O)NH-phenyl, C(O)-furanyl,  $C(O)NH(C_1-C_3)$ alkyl,  $(C_1-C_3)$ alkyl optionally substituted-with up to two substituents

independently selected from OH, halo, (C<sub>1</sub>-C<sub>3</sub>)alkoxy,

pyrrolidinyl, C(O)-pyrrolidinyl, C(O)—N X, and N[(C<sub>1</sub>-C<sub>3</sub>)alkyl]<sub>2</sub>, phenyl optionally substituted with up to two substituents independently selected from (C<sub>1</sub>-C<sub>3</sub>)alkyl, (C<sub>1</sub>-C<sub>3</sub>)alkoxy, halo, CF<sub>3</sub>, and CN, and pyridyl optionally substituted with (C<sub>1</sub>-C<sub>3</sub>)alkyl, CF<sub>3</sub>, and CN, and pyrrolidinyl optionally substituted with up to two substituents independently

30

5

10

15

20

selected from N[( $C_1$ - $C_4$ )alkyl]<sub>2</sub>, C(O)NH<sub>2</sub>, pyridyl, and ( $C_1$ - $C_3$ )alkyl optionally substituted with up to two substituents independently selected from ( $C_1$ - $C_3$ )alkoxy, and pyrrolidinyl;

R<sup>6</sup> is selected from H,

 $(C_1-C_4)$ alkyl optionally substituted with up to two substituents independently selected from OH, halo,  $(C_1-C_4)$ alkoxy, NHC(O) $(C_1-C_3)$ alkyl,

S-(C<sub>1</sub>-C<sub>3</sub>)alkyl, benzimidazolyl, thienyl,

+N $\longrightarrow$ 

 $N[(C_1-C_4)alkyl]_2$  where each alkyl is independently optionally substituted with up to two substituents independently selected from OH,  $(C_1-C_3)alkoxy$ , halo, and phenyl,

phenyl optionally substituted with up to two substituents independently selected from (C<sub>1</sub>-C<sub>3</sub>)alkyl, (C<sub>1</sub>-C<sub>3</sub>)alkoxy, CN, halo,

 $CF_3$ ,  $S(O)_2(C_1-C_3)$ alkyl,  $S(O)_2$ phenyl, and  $S(O)_2NH_2$ , pyridyl optionally substituted up to two times with  $CF_3$ , indolyl optionally substituted up to two times with  $(C_1-C_3)$ alkyl, imidazolyl optionally substituted up to two times with  $(C_1-C_3)$ alkyl, furyl optionally substituted up to two times with  $(C_1-C_4)$ alkyl, and pyrrolidinyl optionally substituted with up to two substituents

independently selected from ( $C_1$ - $C_4$ )alkoxy, (O), and ( $C_1$ - $C_4$ )alkyl optionally substituted with up to two substituents independently selected from OH, ( $C_1$ - $C_3$ )alkoxy, and halo,

indolyl optionally substituted up to two times with  $(C_1-C_3)$ alkyl, pyrazolyl optionally substituted with up to two substituents independently

selected from (C<sub>1</sub>-C<sub>4</sub>)alkyl, (C<sub>3</sub>-C<sub>6</sub>)cycloalkyl, and phenyl optionally substituted with up to two substituents independently

selected from (C<sub>1</sub>-C<sub>4</sub>)alkoxy, (C<sub>1</sub>-C<sub>4</sub>)alkyl, halo, CF<sub>3</sub>, and CN,

benzothiazolyl optionally substituted up to two times with  $(C_1-C_4)$ alkyl, thiazolyl optionally substituted up to two times with  $(C_1-C_4)$ alkyl,

thiadiazolyl optionally substituted with up to two substituents independently

selected from CF<sub>3</sub>, ( $C_3$ - $C_6$ )cycloalkyl, and ( $C_1$ - $C_6$ )alkyl, phenyl optionally substituted with up to two substituents independently selected

from CN, halo,  $CF_3$ ,  $N[(C_1-C_4)alkyl]_2$ , indolyl, ,  $(C_1-C_4)alkoxy$ , O-pyridyl optionally substituted with  $C(O)NH(C_1-C_4)alkyl$ ,  $(C_1-C_4)alkyl$  optionally substituted with up to two substituents

10

5

15

20

25

10

15

20

25

30

independently selected from pyridyl, OH, halo, and phenyl, and

independently substituted with up to two substituents independently

selected from (C<sub>1</sub>-C<sub>3</sub>)alkyl, and(C<sub>1</sub>-C<sub>4</sub>)alkoxy,

pyridyl optionally substituted with phenoxy where said phenoxy is optionally substituted with up to two substituents independently selected from (C<sub>1</sub>-C<sub>4</sub>)alkyl and (C<sub>1</sub>-C<sub>4</sub>)alkoxy, and

indazolyl optionally substituted up to two times with (C<sub>1</sub>-C<sub>4</sub>)alkyl;

R<sup>7</sup> is selected from (C<sub>1</sub>-C<sub>3</sub>)alkoxy, pyrrolidinyl, tetrahydropyranyl,

pyridyl optionally substituted with up to two substituents independently selected from  $(C_1-C_4)$ alkyl and  $(C_1-C_3)$ alkoxy,

pyranyl optionally substituted with up to two substituents independently selected from  $(C_1-C_4)$ alkyl and  $(C_1-C_3)$ alkoxy,

piperidinyl optionally substituted with up to two substituents independently selected from (C<sub>1</sub>-C<sub>3</sub>)alkyl, and (C<sub>1</sub>-C<sub>3</sub>)alkoxy, and

phenyl optionally substituted with up to two substituents independently selected from  $(C_1-C_3)$ alkoxy, and  $(C_1-C_3)$ alkyl; and

X is selected from O, S, CH<sub>2</sub> and NH;

with the proviso that when  $R^1$  is F or Cl, then  $R^4$  must be H, and when  $R^4$  is F or Cl, then  $R^1$  must be H;

or a pharmaceutically acceptable salt thereof.

3. A composition comprising a carrier and a compound of Formula I

wherein

R<sup>1</sup> is selected from H, F, and Cl;

 $R^2$  is selected from H, OH, CN, halo,  $C(O)R^5$ , thienyl, pyrimidinyl, oxazolyl, furanyl,  $(C_1\text{-}C_3) \text{alkyl}, \ (C_2\text{-}C_6) \text{alkenyl} \text{ and } \ (C_2\text{-}C_6) \text{alkynyl}, \text{ each optionally substituted with }$  up to two substituents selected from OH, halo, and  $(C_1\text{-}C_3) \text{alkoxy optionally substituted with } (C_1\text{-}C_3) \text{alkoxy},$ 

(C<sub>1</sub>-C<sub>6</sub>)alkoxy optionally substituted with (C<sub>1</sub>-C<sub>3</sub>)alkyl, (C<sub>1</sub>-C<sub>3</sub>)alkoxy,

10

20

25

30

and  $N[(C_1-C_3)alkyl]_2$  where each alkyl group is independently optionally substituted with a substituent selected from  $(C_1-C_3)alkyl$ ,

 $(C_1-C_3)$ alkoxy OH, halo, +N, and phenyl,

N[(C<sub>1</sub>-C<sub>4</sub>)alkyl]<sub>2</sub> where each alkyl group is independently optionally substituted with up to two substituents independently selected from OH, (C<sub>1</sub>-C<sub>3</sub>)alkyl, halo, (C<sub>1</sub>-C<sub>3</sub>)alkoxy, and phenyl,

pyridyl optionally substituted with up to two substituents independently selected from  $(C_1-C_3)$ alkyl,  $(C_1-C_3)$ alkoxy, and halo,

phenyl optionally substituted with up to two substituents independently selected

from 
$$(C_1-C_3)$$
alkoxy, CN, halo,

 $C(O)N[(C_1-C_3)alkyl]_2$  where each alkyl is optionally substituted with  $(C_1-C_3)alkoxy$ , and

pyrrolidinyl optionally substituted with N[(C1-C3)alkyl]2;

- 15 R<sup>3</sup> is selected from H, halo, (C<sub>1</sub>-C<sub>3</sub>)alkyl, and (C<sub>1</sub>-C<sub>3</sub>)alkoxy;
  - R4 is selected from H, F, and Cl;
  - R<sup>5</sup> is selected from OH, NHR<sup>6</sup>,
    - N[(C<sub>1</sub>-C<sub>3</sub>)alkyl]R<sup>7</sup> where said alkyl is optionally substituted with up to one substituent selected from (C<sub>1</sub>-C<sub>3</sub>)alkyl and (C<sub>1</sub>-C<sub>3</sub>)alkoxy,
    - $N[(C_1-C_3)alkyl]_2$  where each alkyl is optionally substituted with up to two substituents independently selected from CN, OH,  $(C_1-C_3)alkoxy$ ,  $N[(C_1-C_3)alkyl]_2$ , pyridyl, phenyl,  $S(O)_2(C_1-C_3)alkyl$ , tetrahydrofuryl,  $S(O)_2$ -phenyl,  $(C_3-C_6)$ cycloalkyl, and furyl optionally substituted with  $(C_1-C_3)alkyl$ ,
    - $$\label{eq:Newtonicondition} \begin{split} &N[(C_3-C_6)\text{cycloalkyl}](C_1-C_3)\text{alkyl where said alkyl is substituted with up to two}\\ &\text{substituents independently selected from } &(C_1-C_3)\text{alkoxy, OH, CN,}\\ &N[(C_1-C_4)\text{alkyl}]_2,\ &S(O)_2\text{-phenyl, }S(O)_2(C_1-C_3)\text{alkyl, phenyl, furyl,}\\ &\text{tetrahydrofuryl, } &(C_5-C_6)\text{cycloalkyl, and pyridyl,} \end{split}$$
    - optionally substituted with up to two substituents independently selected from  $N[(C_1-C_3)alkyl]_2$ ,  $C(O)(C_1-C_3)alkyl$ , pyrrolidinyl,

 $S(O)_2(C_1-C_3)$ alkyl,  $S(O)_2$ -phenyl,  $\xrightarrow{+}$  , oxo-dihydrobenzimidazolyl, pyrazinyl,  $C(O)NH_2$ , C(O)NH-phenyl, C(O)-furanyl,  $C(O)NH(C_1-C_3)$ alkyl,

 $(C_1-C_3)$ alkyl optionally substituted with up to two substituents independently selected from OH, halo,  $(C_1-C_3)$ alkoxy,

pyrrolidinyl, C(O)-pyrrolidinyl, C(O)-N , and N[(C<sub>1</sub>-C<sub>3</sub>)alkyl]<sub>2</sub>, phenyl optionally substituted with up to two substituents independently selected from (C<sub>1</sub>-C<sub>3</sub>)alkyl, (C<sub>1</sub>-C<sub>3</sub>)alkoxy, halo, CF<sub>3</sub>, and CN, and pyridyl optionally substituted with (C<sub>1</sub>-C<sub>3</sub>)alkyl, CF<sub>3</sub>, and CN, and pyrrolidinyl optionally substituted with up to two substituents independently selected from N[(C<sub>1</sub>-C<sub>4</sub>)alkyl]<sub>2</sub>, C(O)NH<sub>2</sub>, pyridyl, and (C<sub>1</sub>-C<sub>3</sub>)alkyl optionally substituted with up to two substituents independently selected from (C<sub>1</sub>-C<sub>3</sub>)alkoxy, and pyrrolidinyl;

R<sup>6</sup> is selected from H,

(C<sub>1</sub>-C<sub>4</sub>)alkyl optionally substituted with up to two substituents independently selected from OH, halo, (C<sub>1</sub>-C<sub>4</sub>)alkoxy, NHC(O)(C<sub>1</sub>-C<sub>3</sub>)alkyl,

S-(C<sub>1</sub>-C<sub>3</sub>)alkyl, benzimidazolyl, thienyl,

N[(C<sub>1</sub>-C<sub>4</sub>)alkyl]<sub>2</sub> where each alkyl is independently optionally substituted with up to two substituents independently selected from OH, (C<sub>1</sub>-C<sub>3</sub>)alkoxy, halo, and phenyl,

phenyl optionally substituted with up to two substituents independently selected from (C<sub>1</sub>-C<sub>3</sub>)alkyl, (C<sub>1</sub>-C<sub>3</sub>)alkoxy, CN, halo,

CF<sub>3</sub>, S(O)<sub>2</sub>(C<sub>1</sub>-C<sub>3</sub>)alkyl, S(O)<sub>2</sub>phenyl, and S(O)<sub>2</sub>NH<sub>2</sub>, pyridyl optionally substituted up to two times with CF<sub>3</sub>, indolyl optionally substituted up to two times with (C<sub>1</sub>-C<sub>3</sub>)alkyl, imidazolyl optionally substituted up to two times with (C<sub>1</sub>-C<sub>3</sub>)alkyl, furyl optionally substituted up to two times with (C<sub>1</sub>-C<sub>4</sub>)alkyl, and pyrrolidinyl optionally substituted with up to two substituents independently selected from (C<sub>1</sub>-C<sub>4</sub>)alkoxy, (O), and

(C<sub>1</sub>-C<sub>4</sub>)alkyl optionally substituted with up to two substituents independently selected from OH, (C<sub>1</sub>-C<sub>3</sub>)alkoxy, and halo,

indolyl optionally substituted up to two times with (C<sub>1</sub>-C<sub>3</sub>)alkyl, pyrazolyl optionally substituted with up to two substituents independently selected from (C<sub>1</sub>-C<sub>4</sub>)alkyl, (C<sub>3</sub>-C<sub>6</sub>)cycloalkyl, and phenyl optionally substituted with up to two substituents independently selected from (C<sub>1</sub>-C<sub>4</sub>)alkoxy, (C<sub>1</sub>-C<sub>4</sub>)alkyl, halo, CF<sub>3</sub>, and CN,

30

5

10

15

20

10

15

20

25

benzothiazolyl optionally substituted up to two times with (C<sub>1</sub>-C<sub>4</sub>)alkyl, thiazolyl optionally substituted up to two times with (C<sub>1</sub>-C<sub>4</sub>)alkyl, thiadiazolyl optionally substituted with up to two substituents independently selected from CF<sub>3</sub>, (C<sub>3</sub>-C<sub>6</sub>)cycloalkyl, and (C<sub>1</sub>-C<sub>6</sub>)alkyl, phenyl optionally substituted with up to two substituents independently selected

from CN, halo, CF<sub>3</sub>, N[(C<sub>1</sub>-C<sub>4</sub>)alkyl]<sub>2</sub>, indolyl, , (C<sub>1</sub>-C<sub>4</sub>)alkoxy, O-pyridyl optionally substituted with C(O)NH(C<sub>1</sub>-C<sub>4</sub>)alkyl, (C<sub>1</sub>-C<sub>4</sub>)alkyl optionally substituted with up to two substituents independently selected from pyridyl, OH, halo, and phenyl, and

optionally substituted with up to two substituents independently selected from (C<sub>1</sub>-C<sub>3</sub>)alkyl, and(C<sub>1</sub>-C<sub>4</sub>)alkoxy,

pyridyl optionally substituted with phenoxy where said phenoxy is optionally substituted with up to two substituents independently selected from (C<sub>1</sub>-C<sub>4</sub>)alkyl and (C<sub>1</sub>-C<sub>4</sub>)alkoxy, and

indazolyl optionally substituted up to two times with (C<sub>1</sub>-C<sub>4</sub>)alkyl;

R<sup>7</sup> is selected from (C<sub>1</sub>-C<sub>3</sub>)alkoxy, pyrrolidinyl, tetrahydropyranyl,

pyridyl optionally substituted with up to two substituents independently selected from  $(C_1-C_4)$ alkyl and  $(C_1-C_3)$ alkoxy,

pyranyl optionally substituted with up to two substituents independently selected from  $(C_1-C_4)$ alkyl and  $(C_1-C_3)$ alkoxy,

piperidinyl optionally substituted with up to two substituents independently selected from (C<sub>1</sub>-C<sub>3</sub>)alkyl, and (C<sub>1</sub>-C<sub>3</sub>)alkoxy, and

phenyl optionally substituted with up to two substituents independently selected from  $(C_1-C_3)$ alkoxy, and  $(C_1-C_3)$ alkyl; and

X is selected from O, S, CH<sub>2</sub> and NH;

with the proviso that when R<sup>1</sup> is F or Cl, then R<sup>4</sup> must be H, and when R<sup>4</sup> is F or Cl, then R<sup>1</sup> must be H;

or a pharmaceutically acceptable salt thereof.